Key Inclusion Criteria:  Male or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology Relapsed or refractory to, or intolerant of, or refuse approved or standard of care established therapy known to provide clinical benefit for disease At least 1 measurable target lesion that meets the definition of RECIST v1.1 ECOG Performance Status of 0 or 1 Demonstrate adequate organ function Must be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption  Key Exclusion Criteria:  History of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is <5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled Untreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration Active autoimmune diseases or history of autoimmune diseases that may relapse Pregnant or nursing Prior treatment with any SHP2 inhibitors Any condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first study treatment administration Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration